CytomX Therapeutics (NASDAQ:CTMX) Upgraded at Piper Sandler

Piper Sandler upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a neutral rating to an overweight rating in a report published on Tuesday morning, MarketBeat.com reports. Piper Sandler currently has $3.50 price objective on the biotechnology company’s stock, up from their prior price objective of $2.25. A number of other research firms have […]

Related Keywords

Piper Sandler , Seana Mccarthy , Jpmorgan Chase Co , Congress Park Capital , Alphamark Advisors , Jefferies Financial Group , Acadian Asset Management , Sg Americas Securities , Susquehanna Fundamental Investments , Cytomx Therapeutics Inc , Cytomx Therapeutics Company Profile , Securities Exchange Commission , Cytomx Therapeutics , Free Report , Financial Group , Moderate Buy , Get Free Report , Exchange Commission , Mark Advisors , Asset Management , Fundamental Investments , Spark Capital , Cytomx Therapeutics Daily ,